Ssa1-targeted antibody prevents host invasion by Candida albicans
is a commensal fungus that colonizes most healthy individuals' skin and mucosal surfaces but can also cause life-threatening invasive infections, particularly in immunocompromised patients. Despite antifungal treatment availability, drug resistance is increasing, and mortality rates remain unac...
Gespeichert in:
Veröffentlicht in: | Frontiers in microbiology 2023-07, Vol.14, p.1182914-1182914 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | is a commensal fungus that colonizes most healthy individuals' skin and mucosal surfaces but can also cause life-threatening invasive infections, particularly in immunocompromised patients. Despite antifungal treatment availability, drug resistance is increasing, and mortality rates remain unacceptably high. Heat shock protein Ssa1, a conserved member of the Hsp70 family in yeast, is a novel invasin that binds to host cell cadherins, induces host cell endocytosis, and enables
to cause maximal damage to host cells and induces disseminated and oropharyngeal disease.
Here we discovered a mouse monoclonal antibody (mAb 13F4) that targeting
Ssa1 with high affinity (EC
= 39.78 ng/mL). mAb 13F4 prevented
from adhering to and invading human epithelial cells, displayed antifungal activity, and synergized with fluconazole in proof of concept
studies. mAb 13F4 significantly prolonged the survival rate of the hematogenous disseminated candidiasis mice to 75%. We constructed a mAb 13F4 three-dimensional structure using homology modeling methods and found that the antigen-binding fragment (Fab) interacts with the Ssa1 N-terminus.
These results suggest that blocking Ssa1 cell surface function may effectively control invasive
infections and provide a potential new treatment strategy for invasive fungal infections. |
---|---|
ISSN: | 1664-302X 1664-302X |
DOI: | 10.3389/fmicb.2023.1182914 |